1. Home
  2. FUSN

FUSN

Fusion Pharmaceuticals Inc.

Logo Fusion Pharmaceuticals Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-19-2024 3:31pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
.
-
-
%

Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company's focus is on the development of next-generation radiopharmaceuticals as precision medicines for hard-to-treat cancers. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others.

Founded: 2014 Country:
Canada
Canada
Employees: N/A City: HAMILTON
Market Cap: 1.8B IPO Year: 2020
Target Price: $20.86 AVG Volume (30 days): 2.2M
Analyst Decision: Hold Number of Analysts: 12
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.45 EPS Growth: N/A
52 Week Low/High: $2.31 - $21.55 Next Earning Date: 05-09-2024
Revenue: $2,068,000 Revenue Growth: 41.55%
Revenue Growth (this year): -74.45% Revenue Growth (next year): 11.94%

Share on Social Networks: